CRA provided expert reports and trial testimony in trade secret litigation concerning an early-stage oncology product candidate. Plaintiff claimed that the alleged misappropriation led to accelerated development of a competing potential treatment. CRA quantified unjust enrichment using a methodology that measured the value associated with accelerated development, recognizing advantages associated with early versus late entry into the marketplace.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...